Literature DB >> 15336219

Therapeutic use of bacteriophages.

James Soothill, Catherine Hawkins, Erik Anggård, David Harper.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15336219     DOI： 10.1016/S1473-3099(04)01127-2

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  13 in total

1.  Predation in homogeneous and heterogeneous phage environments affects virulence determinants of Pseudomonas aeruginosa.

Authors:  Zeinab Hosseinidoust; Nathalie Tufenkji; Theo G M van de Ven
Journal:  Appl Environ Microbiol       Date:  2013-02-22       Impact factor: 4.792

Review 2.  Phage therapy for respiratory infections.

Authors:  Rachel Yoon Kyung Chang; Martin Wallin; Yu Lin; Sharon Sui Yee Leung; Hui Wang; Sandra Morales; Hak-Kim Chan
Journal:  Adv Drug Deliv Rev       Date:  2018-08-07       Impact factor: 15.470

3.  In vivo growth rates are poorly correlated with phage therapy success in a mouse infection model.

Authors:  J J Bull; G Otto; I J Molineux
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

4.  A tale of tails: Sialidase is key to success in a model of phage therapy against K1-capsulated Escherichia coli.

Authors:  J J Bull; E R Vimr; I J Molineux
Journal:  Virology       Date:  2009-12-16       Impact factor: 3.616

5.  Phage Therapy - Everything Old is New Again.

Authors:  Andrew M Kropinski
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-09       Impact factor: 2.471

6.  Antibacterial efficacy of temperate phage-mediated inhibition of bacterial group motilities.

Authors:  In-Young Chung; Nuri Sim; You-Hee Cho
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

7.  Evolution of Pseudomonas aeruginosa virulence as a result of phage predation.

Authors:  Zeinab Hosseinidoust; Theo G M van de Ven; Nathalie Tufenkji
Journal:  Appl Environ Microbiol       Date:  2013-07-26       Impact factor: 4.792

8.  Antibacterial efficacy of phages against Pseudomonas aeruginosa infections in mice and Drosophila melanogaster.

Authors:  Yun-Jeong Heo; Yu-Rim Lee; Hyun-Hee Jung; JungEun Lee; GwangPyo Ko; You-Hee Cho
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

9.  The role of regulated clinical trials in the development of bacteriophage therapeutics.

Authors:  Helena Mrt Parracho; Ben H Burrowes; Mark C Enright; Malcolm L McConville; David R Harper
Journal:  J Mol Genet Med       Date:  2012-04-23

10.  Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection.

Authors:  Vivek Daniel Paul; Sudarson Sundarrajan; Sanjeev Saravanan Rajagopalan; Sukumar Hariharan; Nanjundappa Kempashanaiah; Sriram Padmanabhan; Bharathi Sriram; Janakiraman Ramachandran
Journal:  BMC Microbiol       Date:  2011-08-31       Impact factor: 3.605
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.